Advances in the treatment of primary brain tumors: Dawn of a new era?

Current Oncology Reports

Volumn 8, Issue 1, 2006, Pages 45-49

  Gilbert, Mark R ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 AMINOCAMPTOTHECIN; ANTICONVULSIVE AGENT; CORTICOSTEROID; ERLOTINIB; GEFITINIB; IRINOTECAN; ISOTRETINOIN; MARIMASTAT; PACLITAXEL; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; VATALANIB;

ALOPECIA; BONE MARROW TOXICITY; BRAIN CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG TARGETING; GENE EXPRESSION; GLIOBLASTOMA; GLIOMA; HUMAN; LIVER TOXICITY; OLIGODENDROGLIOMA; OUTCOMES RESEARCH; OVERALL SURVIVAL; PROGNOSIS; REVIEW; SINGLE DRUG DOSE; THERAPY EFFECT; TREATMENT RESPONSE;

EID: 31544439597     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-006-0008-6     Document Type: Review

References (43)

1. Walker MD, Alexander E Jr, Hunt WE, et al.: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978, 49:333-343.
2. Walker MD, Green SB, Byar DP, et al.: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980, 303:1323-1329.
3. Fine HA, Dear KB, Loeffler JS, et al.: Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993, 71:2585-2597.
4. Stewart LA: Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002, 359:1011-1018.
5. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol 2001, 19:509-518.
6. Stupp R, Mason WP, van den Bent MJ, et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
7. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990, 8:1277-1280.
8. Sorensen AG, Patel S, Harmath C, et al.: Comparison of diameter and perimeter methods for tumor volume calculation. J Clin Oncol 2001, 19:551-557.
9. Warren KE, Patronas N, Aikin AA, et al.: Comparison of one-, two, and three-dimensional measurements of childhood brain tumors. J Natl Cancer Inst 2001, 93:1401-1405.
10. Chen X, Tohme M, Park R, et al.: Micro-PET imaging of alphavbeta3-integrin expression with 18F-labeled dimeric RGD peptide. Mol Imaging 2004, 3:96-104.
11. Jacobs A, Voges J, Reszka R, et al.: Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas. Lancet 2001, 358:727-729.
12. Jacobs AH, Dittmar C, Winkeler A, et al.: Molecular imaging of gliomas. Mol Imaging 2002, 1:309-335.
13. Jacobs AH, Voges J, Kracht LW, et al.: Imaging in gene therapy of patients with glioma. J Neurooncol 2003, 65:291-305.
14. Spence AM, Muzi M, Krohn KA: Molecular imaging of regional brain tumor biology. J Cell Biochem Suppl 2002, 39:25-35.
15. Buckner JC: Factors influencing survival in high-grade gliomas. Semin Oncol 2003, 30 (Suppl 19):10-14.
16. Lamborn KR, Chang SM, Prados MD: Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neurooncology 2004, 6:227-235.
17. Wong ET, Hess KR, Gleason MJ, et al.: Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999, 17:2572.
18. Grant R, Liang BC, Slattery J, et al.: Chemotherapy response criteria in malignant glioma. Neurology 1997, 48:1336-1340.
19. Yung WK, Albright RE, Olson J, et al.: A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000, 83:588-593.
20. Jaeckle KA, Hess KR, Yung WK, et al.: Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol 2003, 21:2305-2311.
21. Groves MD, Puduvalli VK, Hess KR, et al.: Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol 2002, 20:1383-1388.
22. Fetell MR, Grossman SA, Fisher JD, et al.: Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium. J Clin Oncol 1997, 15:3121-3128.
23. Grossman SA, Hochberg F, Fisher J, et al.: Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. The New Approaches to Brain Tumor Therapy. Cancer Chemother Pharmacol 1998, 42:118-126.
24. Gilbert MR, Supko JG, Batchelor T, et al.: Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res 2003, 9:2940-2949.
25. Anderson RC, Elder JB, Brown MD, et al.: Changes in the immunologic phenotype of human malignant glioma cells after passaging in vitro. Clin Immunol 2002, 102:84-95.
26. Chang SM, Kuhn J, Wen P, et al.: Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Invest New Drugs 2004, 22:427-435.
27. Rich JN, Reardon DA, Peery T, et al.: Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004, 22:133-142.
28. Ino Y, Betensky RA, Zlatescu MC, et al.: Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 2001, 7:839-845.
29. Bauman GS, Ino Y, Ueki K, et al.: Allefic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys 2000, 48:825-830.
30. Cairncross G, W, Seiferheld E, Shaw, et al.: An intergroup randomized controlled clinical trial of chemotherapy plus radiation versus RT alone for pure and mixed anaplastic oligodendrogliomas: initial report of RTOG 94-02 [abstract]. Proc ASCO 2004, 23:107.
31. Hill C, Hunter SB, Brat DJ: Genetic markers in glioblastoma: prognostic significance and future therapeutic implications. Adv Anat Pathol 2003, 10:212-217.
32. Mischel PS, Shai R, Shi T, et al.: Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene 2003, 22:2361-2373.
33. Barker FG II, Simmons ML, Chang SM, et al.: EGFR overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2001, 51:410-418.
34. Zhu A, Shaeffer J, Leslie S, et al.: Epidermal growth factor receptor: an independent predictor of survival in astrocytic tumors given definitive irradiation. Int J Radiat Oncol Biol Phys 1996, 34:809-815.
35. Huncharek M, Kupelnick B: Epidermal growth factor receptor gene amplification as a prognostic marker in glioblastoma multiforme: results of a meta-analysis. Oncol Res 2000, 12:107-112.
36. Shinojima N, Tada K, Shiraishi S, et al.: Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003, 63:6962-6970.
37. Waha A, Baumann A, Wolf HK, et al.: Lack of prognostic relevance of alterations in the epidermal growth factor receptor-transforming growth factor-alpha pathway in human astrocytic gliomas. J Neurosurg 1996, 85:634-641.
38. Jaeckle KA, Eyre HJ, Townsend JJ, et al.: Correlation of tumor 06 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol 1998, 16:3310-3315.
39. Esteller M, Garcia-Foncillas J, Andion E, et al.: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000, 343:1350-1354.
40. Hegi ME, Diserens AC, Godard S, et al.: Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004, 10:1871-1874.
41. Hegi ME, Diserens AC, Gorlia T, et al.: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997-1003.
42. Yung WK, Jaekle K, Kyritisis A, et al.: A combination of temozolomide and interferon-alpha in recurrent malignant gliomas, a phase II study. Neuro-oncol 1999, 1:347.
43. Groves MD, Tremont-Lukats TW, Conrad CA, et al.: A phase II trial of temozolomide plus thalidomide (NABTC 99-04) for recurrent glioblastoma multiforme. Neurooncology 2002, 4(Suppl 1):41.